BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16705742)

  • 21. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy.
    Pasquali D; Rossi V; Staibano S; De Rosa G; Chieffi P; Prezioso D; Mirone V; Mascolo M; Tramontano D; Bellastella A; Sinisi AA
    Endocrinology; 2006 Sep; 147(9):4245-51. PubMed ID: 16763065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis.
    Endoh K; Nishi M; Ishiguro H; Uemura H; Miyagi Y; Aoki I; Hirano H; Kubota Y; Ryo A
    Prostate; 2012 May; 72(6):626-37. PubMed ID: 21809350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.
    Yan L; Xing Z; Guo Z; Fang Z; Jiao W; Guo X; Xu Z; Fang Z; Liu Z
    PLoS One; 2013; 8(2):e55790. PubMed ID: 23409045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
    Louis SN; Wang L; Chow L; Rezmann LA; Imamura K; MacGregor DP; Casely D; Catt KJ; Frauman AG; Louis WJ
    Cancer Detect Prev; 2007; 31(5):391-5. PubMed ID: 18031950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines.
    Pflug BR; Reiter RE; Nelson JB
    Prostate; 1999 Sep; 40(4):269-73. PubMed ID: 10420156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
    Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
    Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogens increase the endothelial nitric oxide synthase (ecNOS) mRNA level in LNCaP human prostate carcinoma cells.
    Grande M; Carlström K; Stege R; Pousette A; Faxén M
    Prostate; 2000 Nov; 45(3):232-7. PubMed ID: 11074525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
    Song J; Aumüller G; Xiao F; Wilhelm B; Albrecht M
    Prostate; 2004 Mar; 58(4):394-405. PubMed ID: 14968440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
    Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
    Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
    Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
    Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Over-expression of a poor prognostic marker in prostate cancer: AQP5 promotes cells growth and local invasion.
    Li J; Wang Z; Chong T; Chen H; Li H; Li G; Zhai X; Li Y
    World J Surg Oncol; 2014 Sep; 12():284. PubMed ID: 25217331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Periostin: a promising target of therapeutical intervention for prostate cancer.
    Sun C; Zhao X; Xu K; Gong J; Liu W; Ding W; Gou Y; Xia G; Ding Q
    J Transl Med; 2011 Jun; 9():99. PubMed ID: 21714934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.
    Wu GJ; Wu MW; Wang SW; Liu Z; Qu P; Peng Q; Yang H; Varma VA; Sun QC; Petros JA; Lim SD; Amin MB
    Gene; 2001 Nov; 279(1):17-31. PubMed ID: 11722842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
    Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
    Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.
    van Steenbrugge GJ; Groen M; van Dongen JW; Bolt J; van der Korput H; Trapman J; Hasenson M; Horoszewicz J
    Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state.
    Nadendla SK; Hazan A; Ward M; Harper LJ; Moutasim K; Bianchi LS; Naase M; Ghali L; Thomas GJ; Prowse DM; Philpott MP; Neill GW
    PLoS One; 2011; 6(5):e20271. PubMed ID: 21633508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.